Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.34 - $5.84 $82,425 - $110,913
18,992 Added 182.4%
29,404 $171,000
Q3 2022

Nov 14, 2022

BUY
$4.27 - $7.2 $44,459 - $74,966
10,412 New
10,412 $70,000
Q3 2022

Nov 14, 2022

BUY
$4.27 - $7.2 $44,459 - $74,966
10,412 New
10,412 $70,000
Q2 2022

Aug 16, 2022

SELL
$2.8 - $6.36 $46,555 - $105,747
-16,627 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$2.73 - $3.94 $45,391 - $65,510
16,627 New
16,627 $56,000
Q3 2021

Nov 16, 2021

SELL
$3.17 - $4.15 $83,700 - $109,576
-26,404 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$3.77 - $5.24 $99,543 - $138,356
26,404 New
26,404 $111,000
Q4 2020

Feb 17, 2021

SELL
$9.48 - $12.84 $157,813 - $213,747
-16,647 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$8.67 - $10.82 $144,329 - $180,120
16,647 New
16,647 $163,000
Q1 2018

May 15, 2018

SELL
$19.24 - $28.03 $335,180 - $488,310
-17,421 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$13.96 - $29.05 $243,197 - $506,080
17,421
17,421 $451,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About CONCERT PHARMACEUTICALS, INC.


  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.